Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Cited by (1,008)

Items 501–600 of 1,008

1. Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib
   Dustin M. Walters, James M. Lindberg, Sara J. Adair, Timothy Eric Newhook, Catharine Cowan, Jayme B. Stokes, Cheryl A. Borgman, Edward B. Stelow, Bryce T. Lowrey, Maria E. Chopivsky et al. · 2013 · Neoplasia
2. Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer
   Vincent Channing Tam, Y.J. Ko, Nicole Mittmann, Matthew C. Cheung, Kirushna Kumar, Shazia Hassan, Kelvin Chan · 2013 · Current Oncology
3. Combinational therapy: New hope for pancreatic cancer?
   Si Shi, Wantong Yao, Jin Xu, Jiang Long, Chen Liu, Xianjun Yu · 2011 · Cancer Letters
4. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
   Chiara Caparello, Laura L. Meijer, Ingrid Garajová, Alfredo Falcone, Tessa Y. S. Le Large, Niccola Funel, Geert Kazemier M, Godefridus J. Peters, Enrico Vasile, Elisa Giovannetti · 2016 · World Journal of Gastroenterology
5. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
   Zheng Zhong, Sugunavathi Sepramaniam, Xin Hui Chew, Kris C. Wood, May Ann Lee, Babita Madan, David M. Virshup · 2019 · Oncogene
6. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells
   Shigetsugu Takano, Hideyuki Yoshitomi, Akira Togawa, Kazuyuki Sogawa, Takashi Shida, Fumio Kimura, Hiroaki Shimizu, Takeshi Tomonaga, Fumio Nomura, Masaru Miyazaki · 2007 · Oncogene
7. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
   Debra Hannah Josephs, Danielle S. Fisher, James F. Spicer, Robert James Flanagan · 2013 · Therapeutic Drug Monitoring
8. Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
   Apostolia Maria Tsimberidou, Fadi Braiteh, David J. Stewart, Razelle Kurzrock · 2009 · Journal of Clinical Oncology
9. Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
   Kian‐Huat Lim, Eugene Chung, Adeel S. Khan, Dengfeng Cao, David C. Linehan, Edgar Ben‐Josef, Andrea Wang‐Gillam · 2012 · The Oncologist
10. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer
    Kun Wang, Zhen Chen, Zhiqiang Meng, Junhua Lin, Zhenhua Zhou, Peng Wang, Lianyu Chen, Luming Liu · 2011 · International Journal of Hyperthermia
11. Promise of Wearable Physical Activity Monitors in Oncology Practice
    Muhammad S. Beg, Arjun Gupta, Tyler Francis Stewart, Chad D. Rethorst · 2017 · Journal of Oncology Practice
12. Pancreatic Adenocarcinoma Management
    Yan Jiang, Davendra P. S. Sohal · 2022 · JCO Oncology Practice
13. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
    Klaus B. Mross, Christian Dittrich, Walter E. Aulitzky, Dirk Strumberg, J. Schütte, Roland Michael Schmid, S. Hollerbach, Michael Merger, Gerd Michael Munzert, Frank Fleischer et al. · 2012 · British Journal of Cancer
14. Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors
    Karl‐Hermann Schlingensiepen, Birgit Fischer-Blass, S. Schmaus, S. Ludwig · 2007 · Recent results in cancer research/Recent Results in Cancer Research
15. Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904
    Matthew H. Kulke, Margaret A. Tempero, Donna Niedzwiecki, Donna R. Hollis, Hedy Lee Kindler, Michael Cusnir, Peter C. Enzinger, Stefan M. Gorsch, Richard M. Goldberg, Robert James Mayer · 2009 · Journal of Clinical Oncology
16. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer
    Simone Polvani · 2016 · World Journal of Gastroenterology
17. Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells
    Zeshaan A. Rasheed, Jeanne Kowalski, Benjamin D. Smith, William H. Matsui · 2011 · Stem Cells
18. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
    Masato Ozaka, Yuji Matsumura, Hiroshi Ishii, Yasushi Omuro, Takao Itoi, Hisatsugu Mouri, Keiji Hanada, Yasutoshi Kimura, Iruru Maetani, Yoshinobu Okabe et al. · 2012 · Cancer Chemotherapy and Pharmacology
19. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
    Ulla Klaiber, Carl-Stephan Leonhardt, Oliver Strobel, Christine Tjaden, Thilo Hackert, John P. Neoptolemos · 2018 · Langenbeck s Archives of Surgery
20. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway
    Xin Wang, Xingye Wu, Zhonglin Zhang, Chao Ma, Tingting Wu, Shengli Tang, Zongyue Zeng, Shifeng Huang, Cheng Gong, Chengfu Yuan et al. · 2018 · Scientific Reports
21. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA
    Jee‐Soo Lee, Sung Sup Park, Young Kyung Lee, Jeffrey Allen Norton, Stefanie S. Jeffrey · 2019 · Molecular Oncology
22. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
    Takuji Okusaka, Junji Furuse · 2020 · Journal of Gastroenterology
23. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
    Albrecht Neeße, Thomas Mathias Gress, David A. Tuveson, Patrick Michl, Sebastian Krug · 2013 · OncoTargets and Therapy
24. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review
    George E. Pentheroudakis, F. Anthony Greco, Nicholas A. Pavlidis · 2008 · Cancer Treatment Reviews
25. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    Mitchell Eric Gross, Celestia S. Higano, Allan J. Pantuck, Olga O. Castellanos, Erica Green, KOO N. NGUYEN, David B. Agus · 2007 · BMC Cancer
26. DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance
    Alexey Valeryevich Danilov, Divas Neupane, Archana Sidalaghatta Nagaraja, Elena V. Feofanova, Leigh Ann Humphries, James DiRenzo, Murray Korc · 2011 · PLoS ONE
27. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
    Maarten F. Bijlsma, Hanneke W.M. van Laarhoven · 2015 · Cancer and Metastasis Reviews
28. Fractionated radioimmunotherapy with 90 Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer
    Allyson J. Ocean, Kenneth Lee Pennington, Michael J. Guarino, Arif Sheikh, Tanios Bekaii‐Saab, Aldo N. Serafini, Daniel C. Lee, Max W. Sung, Seza Güleç, Stanley J. Goldsmith et al. · 2012 · Cancer
29. Recent advances in pancreatic cancer: biology, treatment, and prevention
    Divya Kumari Singh, Ghanshyam Upadhyay, Rakesh K. Srivastava, Sharmila Shankar · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
30. Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?
    Rebecca Anne Miksad, Lowell E. Schnipper, Michael Goldstein · 2007 · Journal of Clinical Oncology
31. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence
    Eleanor J. Murray, Ellen C. Caniglia, Lucia C. Petito · 2020 · Research Methods in Medicine & Health Sciences
32. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance
    Rajiv Dua, Jianhua Zhang, Phets Nhonthachit, Elicia M. Penuel, C. Petropoulos, Gordon Parry · 2009 · Breast Cancer Research and Treatment
33. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells
    Shingo Kagawa, Shigetsugu Takano, Hideyuki Yoshitomi, Fumio Kimura, Mamoru Satoh, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Ohtsuka, Atsushi Kato, Katsunori Furukawa et al. · 2012 · Journal of Surgical Research
34. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer
    Hiroshi Imaoka, Nobumasa Mizuno, Kazuo Hara, Susumu Hijioka, Masahiro Tajika, Tsutomu Tanaka, Makoto Ishihara, Tatsuji Yogi, Hideharu Tsutsumi, Toshihisa Fujiyoshi et al. · 2015 · Pancreas
35. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition
    Karl Quint, Manuel Tonigold, Pietro Di Fazio, Roberta Montalbano, Susanne Lingelbach, Felix Rückert, Beate Alinger, Matthias Ocker, Daniel Neureiter · 2012 · International Journal of Oncology
36. Pancreatic Cancer
    Cinthya S. Yabar, Jordan Michael Winter · 2016 · Gastroenterology Clinics of North America
37. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
    Darius Lakdawalla, Jason T. Shafrin, Ningqi Hou, Desi Peneva, Seanna M. Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer, Robert A. Figlin · 2017 · Value in Health
38. Targeted Therapies for Pancreatic Cancer
    Idoroenyi Usua Amanam, Vincent M. Chung · 2018 · Cancers
39. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium
    Mary J. MacKenzie, David L. Saltman, Hal W. Hirte, Jennifer A. Low, C. Johnson, Gregory R. Pond, Malcolm J. Moore · 2007 · Investigational New Drugs
40. Cardio‐Oncology/Onco‐Cardiology
    Robert Hong, Takeshi Iimura, Kenneth N. M. Sumida, Robert M Eager · 2010 · Clinical Cardiology
41. Targeted drug delivery in pancreatic cancer
    Xianjun Yu, Yu‐Qing Zhang, Changyi Chen, Qizhi Cathy Yao, Min Li · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
42. Pancreatic cancer: a review of recent advances
    Florian Eckel, Günter Schneider, Roland Michael Schmid · 2006 · Expert Opinion on Investigational Drugs
43. Erlotinib in the treatment of advanced pancreatic cancer
    Andrew H. Ko · 2008 · Biologics
44. Metabolomics in cell culture—A strategy to study crucial metabolic pathways in cancer development and the response to treatment
    Anna Halama · 2014 · Archives of Biochemistry and Biophysics
45. Hedgehog Promotes Neovascularization in Pancreatic Cancers by Regulating Ang-1 and IGF-1 Expression in Bone-Marrow Derived Pro-Angiogenic Cells
    Kazumasa Nakamura, Junpei Sasajima, Yusuke Mizukami, Yoshiaki Sugiyama, Madoka Yamazaki, Rie Fujii, Toru Kawamoto, Kazuya Koizumi, Kazuya Sato, Mikihiro Fujiya et al. · 2010 · PLoS ONE
46. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation
    Wang, Chengcheng, Zhang, Taiping, Liao, Quan, Dai, Menghua, Guo, Junchao, Yang, Xinyu, Tan, Wen, Lin, Dongxin, Wu, Chen, Zhao, Yupei · 2021 · Protein & Cell
47. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
    Yu. A. Vasyuk, Gennadii Efimovich Gendlin, Elena Ivanovna Emelina, E. Yu. Shupenina, Marina F. Ballyuzek, И. В. Баринова, Marina V. Vitsenya, Igor Leonidovich Davydkin, Дундуа Давид Петрович, Dmitry Viktorovich Duplyakov et al. · 2021 · Russian Journal of Cardiology
48. Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
    Romain Baer, Célia Cintas, Nicole Therville, Julie Guillermet‐Guibert · 2015 · Advances in Biological Regulation
49. Pancreatic cancer stem cells – update and future perspectives
    Enza Lonardo, Patrick Christian Hermann, Christopher Heeschen · 2010 · Molecular Oncology
50. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
    Fabienne Thomas, Philippe Rochaix, Mélanie White‐Koning, Isabelle Hennebelle, Jérôme Sarini, Adil Benlyazid, Laurence Malard, Jean‐Louis Lefebvre, Étienne Chatelut, Jean Pierre Delord · 2009 · European Journal of Cancer
51. Randomized Phase II Trials: Inevitable or Inadvisable?
    Hui Kong Gan, Axel Grothey, Gregory R. Pond, Malcolm J. Moore, Lillian L. Siu, Daniel J. Sargent · 2010 · Journal of Clinical Oncology
52. Neuropilin-2–Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma
    Nikolaos A. Dallas, Michael Jeffrey Gray, Ling Xia, Fan Fan, George Van Buren, Puja Gaur, Shaija Samuel, Sherry J. Lim, Thiruvengadam Arumugam, Vijaya Ramachandran et al. · 2008 · Clinical Cancer Research
53. Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non–Small-Cell Lung Cancer Cells
    Min‐Shao Tsai, Ya‐Hsun Kuo, Yu‐Fan Chiu, Ying-Chen Su, Yun‐Wei Lin · 2010 · Journal of Pharmacology and Experimental Therapeutics
54. New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
    Howard A. Burris, Caio Rocha‐Lima · 2008 · The Oncologist
55. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
    Susanne Schüler, Petra Fritsche, Sandra Diersch, Alexander Arlt, Roland Michael Schmid, Dieter Saur, Günter Schneider · 2010 · Molecular Cancer
56. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel
    Jean‐Luc Van Laethem, Chris Verslype, Juan Iovanna, Patrick Michl, Thierry Conroy, Christophe Louvet, Pascal R. Hammel, Emmanuel Mitry, Michel Pierre Ducreux, T. Maraculla et al. · 2011 · Annals of Oncology
57. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno B. Riess, Uwe Pelzer, Andreas Hilbig, Jens Stieler, Bernhard Opitz, Theo Scholten, D Kauschat-Brüning, Peter Bramlage, Bernd Dörken, Helmut Oettle · 2008 · BMC Cancer
58. Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
    Sebastian Stintzing, Christine Kapaun, Rüdiger Paul Laubender, Andreas Jung, Jens H. L. Neumann, Dominik Paul Modest, Clemens Albrecht Giessen, Nicolas Moosmann, Andreas Wollenberg, Thomas Kirchner et al. · 2012 · International Journal of Cancer
59. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy
    Christian Hirt, Tijmen H. Booij, Linda Grob, Patrik Simmler, Nora C. Toussaint, David Keller, Doreen Taube, Vanessa Ludwig, Alexander Goryachkin, Chantal Pauli et al. · 2022 · Cell Genomics
60. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
    Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan et al. · 2023 · Journal of Experimental & Clinical Cancer Research
61. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
    Ya-Fei Du, Feride Karatekin, Wendy Kehan Wang, Wanjin Hong, T. K. B. Gandhi · 2025 · Pharmacological Reviews
62. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
    Ian Chau, David Cunningham, Christopher Russell, A. R. Norman, Tom R. Kurzawinski, Peter Harper, Phil M. Harrison, Gary Middleton, Fred. H. Daniels, Tamas Hickish et al. · 2006 · British Journal of Cancer
63. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo
    Yongwei Wang, Shuangjia Wang, Yinan Zhou, Shangha Pan, Bei Sun · 2012 · Journal of Cancer Research and Clinical Oncology
64. Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
    Sant P. Chawla, Victoria S. Chua, Lita Fernandez, Dorris Quon, William C. Blackwelder, Erlinda Maria Gordon, Frederick L. Hall · 2009 · Molecular Therapy
65. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
    Steven Attia, Jill Kolesar, Michelle R. Mahoney, Henry Clement Pitot, Daniel A. Laheru, James M. Heun, Wei Huang, Jens C. Eickhoff, Charles Erlichman, Kyle D. Holen · 2008 · Investigational New Drugs
66. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
    Shadan S. Ali, Sanjeev Banerjee, Aamir Ahmad, Bassel F. El‐Rayes, Philip A. Philip, Fazlul H. Sarkar · 2008 · Molecular Cancer Therapeutics · Retracted
67. Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
    Piergiorgio Pettazzoni, Andrea Viale, Parantu K. Shah, Alessandro Carugo, Haoqiang Ying, Huamin Wang, Giannicola Genovese, Sahil Seth, Rosalba Minelli, Tessa Green et al. · 2015 · Cancer Research
68. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
    Laëtitia Dahan, Frank Bonnetain, Marc Ychou, Emmanuel Mitry, Mohamed Gasmi, Jean‐Luc Raoul, Stéphane Cattan, Jean–Marc Phelip, Pascal R. Hammel, Bruno Chauffert et al. · 2010 · Gut
69. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
    Matthias Breidert, Richard Fischer, Tobias Keck, Frank Makowiec, Christian Lohrmann, Jan Harder · 2012 · Saudi Journal of Gastroenterology
70. Drug-induced hepatotoxicity in cancer patients - implication for treatment
    Bruno Vincenzi, Grazia Armento, Mariella Spalato Ceruso, Giovanna Catania, Mark Leakos, Daniele Santini, Giorgio Minotti, Giuseppe Tonini · 2016 · Expert Opinion on Drug Safety
71. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
    Justin Han-Je Lo, Liangliang Hao, Mandar Deepak Muzumdar, Srivatsan Raghavan, Ester J. Kwon, Emilia M. Pulver, Felicia Hsu, Andrew J. Aguirre, Brian Matthew Wolpin, Charles S. Fuchs et al. · 2018 · Molecular Cancer Therapeutics
72. RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
    Depeille, Philippe, Henricks, Linda M., van de Ven, Robert A. H., Lemmens, Ed, Wang, Chih-Yang, Matli, Mary, Werb, Zena, Haigis, Kevin M., Donner, David, Warren, Robert et al. · 2015 · Nature Cell Biology
73. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
    Tang, Daolin, Kroemer, Guido, Kang, Rui · 2021 · Molecular Cancer
74. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
    Richards, D.A., Boehm, K.A., Waterhouse, D.M., Wagener, D.J., Krishnamurthi, S.S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M. et al. · 2006 · Annals of Oncology
75. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer
    Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song · 2014 · Cancer Immunology Immunotherapy
76. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
    Eric Van Cutsem, Mario A. Dicato, Nadir Arber, Jordan D. Berlin, Andrès M.R. Cervantes, Fortunato Ciardiello, Aimery de Gramont, Eduardo Díaz‐Rubio, Michel Pierre Ducreux, Ravit Geva et al. · 2010 · Annals of Oncology
77. Digestive cancers: mechanisms, therapeutics and management
    Tianzuo Zhan, Johannes Betge, Nadine Schulte, Lena Dreikhausen, Michael Hirth, Moying Li, Philip Weidner, Antonia Leipertz, Andreas Teufel, Matthias P A Ebert · 2025 · Signal Transduction and Targeted Therapy
78. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer
    Howard S. Höchster, Daniel G. Haller, Aimery de Gramont, Jordan D. Berlin, Philip A. Philip, Malcolm J. Moore, Jaffer A. Ajani · 2006 · Cancer
79. Targeted therapies in bladder cancer—an update
    Peter C. Black, Piyush Kumar Agarwal, Colin P. Dinney · 2007 · Urologic Oncology Seminars and Original Investigations
80. Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway
    Weitian Wei, Hui Chen, Zhaohong Wang, Zhonglin Ni, Haibin Liu, Hongfei Tong, Hongchun Guo, DIAN-LEI LIU, Shengzhang Lin · 2012 · International Journal of Biological Sciences
81. Molecularly targeted therapies in cervical cancer. A systematic review
    Flora Zagouri, Theodoros Ν. Sergentanis, Dimosthenis Chrysikos, Martin Filipits, Rupert Bartsch · 2012 · Gynecologic Oncology
82. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
    Gabriela Bernadeta Iwanski, Dhong H Lee, Shlomit Y. Ein-Gal, Ngan Doan, Brandon Castor, Marco Vogt, Melvin Toh, Carsten Bokemeyer, JONATHAN W. SAID, Nils Heinrich Thoennissen et al. · 2010 · British Journal of Pharmacology
83. Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
    Xiaohai Li, Theodore M. Kamenecka, Michael D. Cameron · 2010 · Drug Metabolism and Disposition
84. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients
    Masayuki Sho, Yoshiaki Murakami, Fuyuhiko Motoi, Sohei Satoi, Ippei Matsumoto, Manabu Kawai, Goro Honda, Kenichiro Uemura, Hiroaki Yanagimoto, Masanao Kurata et al. · 2014 · Journal of Gastroenterology
85. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies
    Jill Palmer Smith, Lionel Aurelien Kankeu Fonkoua, Terry W. Moody · 2016 · International Journal of Biological Sciences
86. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review
    Rahib, Lola, Fleshman, Julie M., Matrisian, Lynn M., Berlin, Jordan D. · 2016 · JAMA Oncology
87. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma
    Yasuyuki Okada, Naoki Takahashi, Tetsuji Takayama, Ajay Goel · 2021 · Carcinogenesis
88. Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
    Martine Humbert, Nathalie Castéran, Sébastien Letard, Katia Hanssens, Juan Iovanna, Pascal Finetti, François Bertucci, Thomas Bader, Colin D. Mansfield, Alain Moussy et al. · 2010 · PLoS ONE
89. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
    Nikolaos Ioannou, Angus George Dalgleish, Alan Michael Seddon, David Mackintosh, Ulrich Gürtler, Flavio Solca, Helmout Modjtahedi · 2011 · British Journal of Cancer
90. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
    Stefan Hubert Boeck, Thomas Hoehler, Gernot Seipelt, Rolf Mahlberg, A. Wein, Andreas Hochhaus, Hans-Peter Böck, B. Schmid, Erika Kettner, Martina Beate Stauch et al. · 2007 · Annals of Oncology
91. A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
    Carlos L. Arteaga, Anne O’Neill, Stacy L. Moulder, Michael Pins, Joseph A. Sparano, George W. Sledge, Nancy E. Davidson · 2008 · Clinical Cancer Research
92. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
    Austin G. Duffy, Jeremy S. Kortmansky, Gary K. Schwartz, Marinela Capanu, S. A. Puleio, Bruce D. Minsky, Leonard B. Saltz, Eileen Mary O'Reilly, David Paul Kelsen · 2007 · Annals of Oncology
93. Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    Jonathan Wade Goldman, Isett Laux, Feng Chai, Ronald E. Savage, Dora Ferrari, Edward Graeme Garmey, Richard G. Just, Lee S. Rosen · 2012 · Cancer
94. CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR
    Tianxiao Wang, Jingxuan Yang, Jianwei Xu, Jian Li, Zhe Cao, Li Zhou, Lei You, Hong Shu, Zhaohui Lu, Hui‐Hua Li et al. · 2014 · Oncotarget
95. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma
    Maurizio Cantore, Roberto Girelli, Andrea Mambrini, Isabella M. Frigerio, G. Boz, Roberto Salvia, Alessandro Giardino, M. Orlandi, Alessandra Auriemma, Claudio Bassi · 2012 · British journal of surgery
96. Rexin-G, a targeted genetic medicine for cancer
    Erlinda Maria Gordon, Frederick L. Hall · 2010 · Expert Opinion on Biological Therapy
97. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
    Jing Hu, Gang Zhao, Hongxia Wang, Lei Tang, Yingchun Xu, Yue Ma, Fengchun Zhang · 2011 · Journal of Hematology & Oncology
98. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Emma Guttman‐Yassky, Alain C. Mita, Maja J.A. de Jonge, Lesley Matthews, Sean P. McCarthy, Kenneth K. Iwata, Jaap Verweij, Eric Keith Rowinsky, James G. Krueger · 2010 · European Journal of Cancer
99. Smarter drugs emerging in pancreatic cancer therapy
    Alexander Kleger, Lukas Perkhofer, Thomas Theodor Werner Seufferlein · 2014 · Annals of Oncology
100. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
     Mubin Tarannum, Juan Luis Vivero-Escoto · 2022 · Advanced Drug Delivery Reviews